SACRAMENTO: Gilead Sciences Inc. and Immunomedics have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88/share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020….